Photobiomodulation in Head and Neck Cancer-Related Chronic Lymphedema

The U.S. Food and Drug Administration approved photobiomodulation therapy (PBMT) as a treatment for breast cancer-related arm lymphedema (BCRL) in 2006. The investigators conducted two pilot clinical trials. Results demonstrated the feasibility, acceptability, and preliminary efficacy of PBMT for the treatment of chronic lymphedema in head and neck cancer (HNC) survivors. The objective of this study is to further investigate and confirm the positive effects of PBMT on HNC-related chronic lymphedema.

Trial Details

NCT ID
NCT06837480
Phase
NA
Sponsor
Abramson Cancer Center at Penn Medicine
Status
RECRUITING
Cancer Type
Head and Neck Cancer
Interventions
  • LTU-904 Portable Laser Therapy Unit (active laser device)
  • LTU-904 Portable Laser Therapy Unit (sham/inactive laser device)
Locations (sample)
  • Philadelphia, Pennsylvania, United States|39.95238,-75.16362
  • Nashville, Tennessee, United States|36.16589,-86.78444

Key Eligibility Criteria

  • \>18 years of age Biopsy proven head and neck cancer No evidence of cancer at the time of study enrollment, between 12- and 60-month post-cancer tr…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Head and Neck Cancer Trials on Trialify →